Evogene (EVGN) Total Current Liabilities (2016 - 2025)
Evogene (EVGN) posted Total Current Liabilities of $3.4 million for Q4 2025, down 77.33% sequentially from $15.2 million in Q2 2025, and down 81.58% YoY from $18.7 million in Q4 2024.
Evogene (EVGN) Total Current Liabilities (2016 - 2025) Analysis & Trends
Evogene has reported Total Current Liabilities for 10 years, with the latest figure at $3.4 million in Q4 2025.
- Quarterly Total Current Liabilities fell 81.58% year-over-year to $3.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.4 million (down 81.58% YoY) and the FY2025 annual result came in at $3.4 million, down 81.58% from the prior year.
- Total Current Liabilities eased to $3.4 million in Q4 2025 per EVGN's latest filing, from $15.2 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $18.7 million in Q4 2024 and troughed at $3.4 million in Q4 2025.
- A 5-year average of $9.0 million and a median of $6.6 million in 2021 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities surged 169.23% in 2024, then slumped 81.58% in 2025.
- Over 5 years, Total Current Liabilities stood at $6.9 million in 2021, then fell by 18.27% to $5.6 million in 2022, then rose by 23.45% to $6.9 million in 2023, then surged by 169.23% to $18.7 million in 2024, then plunged by 81.58% to $3.4 million in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $3.4 million, $15.2 million, and $18.7 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.44 Mn |
| Jun 30, 2025 | 15.19 Mn |
| Dec 31, 2024 | 18.70 Mn |
| Jun 30, 2024 | 16.29 Mn |
| Dec 31, 2023 | 6.94 Mn |
| Jun 30, 2023 | 6.39 Mn |
| Dec 31, 2022 | 5.63 Mn |
| Jun 30, 2022 | 5.54 Mn |
| Dec 31, 2021 | 6.88 Mn |
| Jun 30, 2021 | 5.33 Mn |
| Dec 31, 2020 | 9.68 Mn |
| Jun 30, 2020 | 4.82 Mn |
| Dec 31, 2019 | 5.75 Mn |
| Dec 31, 2018 | 5.43 Mn |
| Dec 31, 2017 | 4.66 Mn |
| Dec 31, 2016 | 5.23 Mn |